Artivion (NYSE:AORT) Rating Reiterated by Needham & Company LLC

Artivion (NYSE:AORT)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a report issued on Friday, Benzinga reports. They currently have a $30.00 price target on the stock. Needham & Company LLC’s price objective suggests a potential upside of 16.32% from the company’s previous close.

AORT has been the topic of a number of other research reports. Oppenheimer upped their price objective on Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Lake Street Capital upped their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Finally, Stifel Nicolaus increased their price target on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th.

Artivion Stock Up 1.9 %

Shares of AORT stock opened at $25.79 on Friday. The firm has a fifty day moving average of $25.85 and a 200-day moving average of $23.81. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -107.46 and a beta of 1.74. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07. Artivion has a 12-month low of $12.16 and a 12-month high of $29.24.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The company had revenue of $98.02 million during the quarter, compared to analysts’ expectations of $97.70 million. As a group, equities research analysts predict that Artivion will post 0.2 earnings per share for the current fiscal year.

Insider Activity

In other Artivion news, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the transaction, the director now owns 34,159 shares of the company’s stock, valued at $853,633.41. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, SVP Jean F. Holloway sold 2,383 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $25.76, for a total transaction of $61,386.08. Following the sale, the senior vice president now owns 165,099 shares of the company’s stock, valued at approximately $4,252,950.24. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total value of $242,627.91. Following the sale, the director now owns 34,159 shares in the company, valued at approximately $853,633.41. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,679 shares of company stock worth $626,518. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AORT. Perceptive Advisors LLC boosted its position in Artivion by 4.7% during the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after buying an additional 124,725 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Artivion by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock worth $392,000 after purchasing an additional 481 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Artivion in the second quarter worth $366,000. Public Sector Pension Investment Board grew its stake in shares of Artivion by 7.8% in the second quarter. Public Sector Pension Investment Board now owns 87,273 shares of the company’s stock worth $2,239,000 after purchasing an additional 6,344 shares during the last quarter. Finally, RW Investment Management LLC acquired a new stake in Artivion in the second quarter valued at $219,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.